At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,014 enrolled
Drug / intervention
Ferumoxytol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
In Brief
A Phase 3 clinical trial evaluating Ferumoxytol and FCM for Iron Deficiency Anemia. Completed, enrolled 2,014 participants across 127 sites in 7 countries.
Detailed Summary
To evaluate the safety of 1.020 grams (g) of intravenous (IV) ferumoxytol compared to 1.500 g of IV ferric carboxymaltose (FCM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIron Deficiency Anemia
CountriesCanada, Hungary, Latvia, Lithuania, Poland, Puerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedMar 2016
Primary CompletionJan 2017
Study CompletionJul 2017
TodayJul 2026
First PostedMar 1, 2016
Enrollment StartFeb 29, 2016
Primary CompletionJan 16, 2017
Study CompletionJul 17, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.3 years ago
Interventions
Ferumoxytoldrug
FCMdrug